[1] |
MORRISON JD, MENDOZA-ELIAS N, LIPNIK AJ, et al. Gastric varices bleed at lower portosystemic pressure gradients than esophageal varices[J]. J Vasc Interv Radiol, 2018, 29( 5): 636- 641. DOI: 10.1016/j.jvir.2017.10.014.
|
[2] |
Chinese Society of Hepatology, Chinese Society of Gastroenterology, and Chinese Society of Digestive Endoscopology of Chinese Medical Association. Guidelines on the management of esophagogastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2023, 39( 3): 527- 538.
中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会消化内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2023, 39( 3): 527- 538.
|
[3] |
de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno VII-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76( 4): 959- 974. DOI: 10.1016/j.jhep.2021.12.022.
|
[4] |
DENG H, QI X, PENG Y, et al. Diagnostic accuracy of APRI, AAR, FIB-4, FI, and King Scores for diagnosis of esophageal varices in liver cirrhosis: A retrospective study[J]. Med Sci Monit, 2015, 21: 3961- 3977. DOI: 10.12659/msm.895005.
|
[5] |
YAN YJ, LI Y, FAN CL, et al. A novel machine learning-based radiomic model for diagnosing high bleeding risk esophageal varices in cirrhotic patients[J]. Hepatol Int, 2022, 16( 2): 423- 432. DOI: 10.1007/s12072-021-10292-6.
|
[6] |
GINES P, KRAG A, ABRAIDES JG, et al. Liver cirrhosis[J]. Lancet, 2021, 398( 10308): 1359- 1376. DOI: 10.1016/S0140-6736(21)01374-X
|
[7] |
PARK JJ, PARK JY, KIM DY, et al. Prediction of significant fibrosis in chronic hepatitis C patients with normal ALT[J]. Hepatogastroenterology, 2011, 58( 109): 1321- 1327. DOI: 10.5754/hge11041.
|
[8] |
Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. Chin J Infect Dis, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.
中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.
|
[9] |
Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
|
[10] |
SUN DY. Predictive value of FIB-4, Lok and King scores for esophageal varices in liver cirrhosis[D]. Hefei: Anhui Medical University, 2021.
孙迪一. FIB-4、Lok和King评分对肝硬化食管静脉曲张的预测价值[D]. 合肥: 安徽医科大学, 2021.
|
[11] |
LI N, ZHENG SQ, ZHAO SS. Application of FibroS can, APRI, FIB-4 and GPR in prediction of esophageal varices in patients with liver cirrhosis[J]. J Pract Hepatol, 2020, 23( 4): 560- 563. DOI: 10.3969/j.issn.1672-5069.2020.04.027.
李娜, 郑少秋, 赵守松. FibroScan联合多种预测模型预测肝硬化患者食管静脉曲张程度应用价值探讨[J]. 实用肝脏病杂志, 2020, 23( 4): 560- 563. DOI: 10.3969/j.issn.1672-5069.2020.04.027.
|
[12] |
ZHU X, XI XL, HAN JT. Predictive value of serum fibrosis index-4 APRI AAR for esophageal and gastric varices in patients with hepatitis B cirrhosis[J]. Med Forum, 2024, 28( 1): 22- 25. DOI: 10.19435/j.1672-1721.2024.01.007.
朱欣, 习晓丽, 韩江涛. 血清学指标纤维化指数-4 APRI AAR对乙型肝炎肝硬化患者食管胃底静脉曲张的预测价值[J]. 基层医学论坛, 2024, 28( 1): 22- 25. DOI: 10.19435/j.1672-1721.2024.01.007.
|
[13] |
WANG SM, WANG N, YU Z, et al. Diagnostic values of APRI, AAR, and FIB-4 predictive models in autoimmune cirrhosis combined with esophagogastric fundal varices[J]. J Jilin Univ(Med Ed), 2024, 50( 2): 523- 528. DOI: 10.13481/j.1671-587X.20240227.
王素梅, 王楠, 于珍, 等. APRI、AAR和FIB-4等预测模型对自身免疫性肝硬化伴食管胃底静脉曲张的诊断价值[J]. 吉林大学学报(医学版), 2024, 50( 2): 523- 528. DOI: 10.13481/j.1671-587X.20240227.
|
[14] |
CHEN ZM, HUANG DY, LIU HY, et al. Clinical value of transient elastography combined with aspartate aminotransferase to platelet ratio index and fibrosis index based on four factors for predicting the severity of esophageal varices in hepatic cirrhosis[J]. Acad J Guangzhou Med Univ, 2016, 44( 2): 22- 25. DOI: 10.3969/j.issn.1008-1836.2016.02.006.
陈志敏, 黄德扬, 刘惠媛, 等. 瞬时弹性成像联合天冬氨酸转氨酶/血小板比值指数和FIB-4指数预测肝硬化食管静脉曲张程度的临床价值[J]. 广州医科大学学报, 2016, 44( 2): 22- 25. DOI: 10.3969/j.issn.1008-1836.2016.02.006.
|
[15] |
WAI CT, GREENSON JK, FONTANA RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C[J]. Hepatology, 2003, 38( 2): 518- 526. DOI: 10.1053/jhep.2003.50346.
|
[16] |
GIANNINI E, RISSO D, BOTTA F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease[J]. Arch Intern Med, 2003, 163( 2): 218- 224. DOI: 10.1001/archinte.163.2.218.
|
[17] |
VALLET-PICHARD A, MALLET V, NALPAS B, et al. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest[J]. Hepatology, 2007, 46( 1): 32- 36. DOI: 10.1002/hep.21669.
|
[18] |
OHTA T, SAKAGUCHI K, FUJIWARA A, et al. Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level[J]. Acta Med Okayama, 2006, 60( 2): 77- 84. DOI: 10.18926/AMO/30729.
|
[19] |
QI XS, LI HY, CHEN J, et al. Serum liver fibrosis markers for predicting the presence of gastroesophageal varices in liver cirrhosis: A retrospective cross-sectional study[J]. Gastroenterol Res Pract, 2015, 2015: 274534. DOI: 10.1155/2015/274534.
|
[20] |
ZHOU JL, WANG BQ, SUN YM, et al. Application value of liver stiffness measurement-to-platelet ratio index score in diagnosis of hepatitis B liver fibrosis and liver cirrhosis[J]. J Clin Hepatol, 2022, 38( 7): 1529- 1533. DOI: 10.3969/j.issn.1001-5256.2022.07.014.
周家玲, 王冰琼, 孙亚朦, 等. LPRI评分在乙型肝炎肝纤维化及肝硬化中的诊断价值[J]. 临床肝胆病杂志, 2022, 38( 7): 1529- 1533. DOI: 10.3969/j.issn.1001-5256.2022.07.014.
|
[21] |
SEBASTIANI G, TEMPESTA D, FATTOVICH G, et al. Prediction of oesophageal varices in hepatic cirrhosis by simple serum non-invasive markers: Results of a multicenter, large-scale study[J]. J Hepatol, 2010, 53( 4): 630- 638. DOI: 10.1016/j.jhep.2010.04.019.
|
[22] |
TAFAREL JR, TOLENTINO LHL, CORREA LM, et al. Prediction of esophageal varices in hepatic cirrhosis by noninvasive markers[J]. Eur J Gastroenterol Hepatol, 2011, 23( 9): 754- 758. DOI: 10.1097/MEG.0b013e3283488a88.
|
[23] |
DENG H, QI XS, GUO XZ. Diagnostic accuracy of APRI, AAR, FIB-4, FI, king, lok, forns, and FibroIndex scores in predicting the presence of esophageal varices in liver cirrhosis: A systematic review and meta-analysis[J]. Medicine(Baltimore), 2015, 94( 42): e1795. DOI: 10.1097/MD.0000000000001795.
|
[24] |
BERZIGOTTI A, GILABERT R, ABRALDES JG, et al. Noninvasive prediction of clinically significant portal hypertension and esophageal varices in patients with compensated liver cirrhosis[J]. Am J Gastroenterol, 2008, 103( 5): 1159- 1167. DOI: 10.1111/j.1572-0241.2008.01826.x.
|
[1] | Yishan LIU, Lanting ZHANG, Yunyu ZHAO, Fanpu JI, Qinglei ZENG. Management of hepatitis C in children and pregnant women[J]. Journal of Clinical Hepatology, 2024, 40(4): 654-658. doi: 10.12449/JCH240402 |
[2] | Jing KUANG, Shuangqin TENG, Tongtong SHEN, Yiran YAN, Wei WANG, Chuan SHEN, Caiyan ZHAO. Risk factors for portopulmonary hypertension in liver cirrhosis and construction of a predictive model[J]. Journal of Clinical Hepatology, 2024, 40(9): 1802-1806. doi: 10.12449/JCH240914 |
[3] | Shanshan XU, Lixia QIU, Yali LIU, Jing ZHANG. Risk factors and predictive models for liver cancer after sustained virologic response in hepatitis C[J]. Journal of Clinical Hepatology, 2024, 40(6): 1259-1263. doi: 10.12449/JCH240629 |
[4] | Tianfu LIU, Liang WANG, Lingyi ZHANG. Risk factors for non-neoplastic portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(9): 2122-2127. doi: 10.3969/j.issn.1001-5256.2023.09.014 |
[5] | Gong FENG, Juanjuan SONG, Feng YE, Yonghong MA, Yilin REN, Ziyi ZHANG, Na HE, Xueping LI, Man MI. Recompensation of liver cirrhosis: Current status and challenges[J]. Journal of Clinical Hepatology, 2023, 39(10): 2464-2469. doi: 10.3969/j.issn.1001-5256.2023.10.027 |
[6] | Bingbing ZHU, Jinxiang YANG, Qun ZHANG, Fangyuan GAO, Xianbo WANG. Risk factors for the 90-day prognosis of patients with type I hepatorenal syndrome and establishment of a predictive model[J]. Journal of Clinical Hepatology, 2022, 38(7): 1561-1565. doi: 10.3969/j.issn.1001-5256.2022.07.019 |
[7] | Siqin LIU, Xiaomei WANG, Xia LI, Luwen LIANG, Ke WANG, Rui WANG. Covert hepatic encephalopathy in liver cirrhosis: Risk factors and prognosis[J]. Journal of Clinical Hepatology, 2022, 38(2): 359-364. doi: 10.3969/j.issn.1001-5256.2022.02.020 |
[8] | Jiajia RUAN, Shifei WEN, Xia WANG, Li LI, Juanjuan FU, Xiucheng PAN. Influencing factors for recompensation in patients with first-time decompensated hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(8): 1796-1800. doi: 10.3969/j.issn.1001-5256.2022.08.015 |
[9] | Zhiying HE, Bingqiong WANG, Hong YOU. Liver cirrhosis: Decompensation and "recompensation"[J]. Journal of Clinical Hepatology, 2022, 38(5): 1002-1005. doi: 10.3969/j.issn.1001-5256.2022.05.006 |
[10] | Shanshan LI, Manman XU, Zhongping DUAN, Yu CHEN. Risk factors for liver cirrhosis in acute-on-chronic liver failure patients without liver cirrhosis in the convalescence stage[J]. Journal of Clinical Hepatology, 2021, 37(12): 2824-2829. doi: 10.3969/j.issn.1001-5256.2021.12.019 |
[11] | LI ZhengHong, DONG YuWei, LU LunGen. Risk factors,diagnosis,and updated classification of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2411-2414. doi: 10.3969/j.issn.1001-5256.2020.11.003 |
[12] | Ruan FangMing, Li BiMin. Risk factors for the formation of portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 182-185. doi: 10.3969/j.issn.1001-5256.2020.01.043 |
[13] | Lyu Jing, Dong SiSi, Gu HongTu, Zhao ZhangQing, Liu ChengHai. TCM syndrome characteristics of portal vein thrombosis in patients with liver cirrhosis and related risk factors[J]. Journal of Clinical Hepatology, 2019, 35(10): 2210-2213. doi: 10.3969/j.issn.1001-5256.2019.10.016 |
[14] | He Yang, Su YaRong, Han ZiYan. Current status of research on primary and secondary risk factors for esophagogastric variceal rebleeding in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(7): 1555-1559. doi: 10.3969/j.issn.1001-5256.2018.07.041 |
[15] | Jin Yan, Wang Xue, Zhang LingJuan, Qiu Ting, Shang BoXin, Lian XiaoYan, Yan ChunYing, Duan TianJiao, Zhang Rong, Liu GuiSheng. Risk factors for early rebleeding after esophageal variceal ligation in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2017, 33(11): 2147-2151. doi: 10.3969/j.issn.1001-5256.2017.11.019 |
[16] | Yu ZhiRui, Wei GuoXi, Liu QiChang, Jin PeiMin. Risk factors for HBV-related liver cirrhosis complicated by acute upper gastrointestinal bleeding[J]. Journal of Clinical Hepatology, 2017, 33(5): 860-863. doi: 10.3969/j.issn.1001-5256.2017.05.013 |
[17] | Zhou RenHua, Li Peng, Zhang YanTing, Yang Hua, Yang ShaoQi. Clinical manifestations of portal vein thrombosis and related risk factors in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(2): 275-278. doi: 10.3969/j.issn.1001-5256.2016.02.015 |
[18] | Yang Hua, Liu YunXia, Li Peng, Yang ShaoQi, Wang YuanZhen. Analysis of risk factors for early rebleeding from esophageal and gastric varices in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(6): 540-542. doi: 10.3969/j.issn.1001-5256.2014.06.015 |
[19] | Wang Hong. Risk factors for patients with cirrhosis developed renal dysfunction[J]. Journal of Clinical Hepatology, 2004, 20(2): 101-102. |